Topical Losartan For The Treatment Of Corneal Scarring: Preliminary Results From An Ongoing Prospective Case Study

Published 2026 - 44th Congress of the ESCRS

Reference: POCOR206 | Type: Poster | DOI: 10.82333/m38q-d181

Authors: Mr Paul Emesz* ¹ , Dr Lina Farhoumand ¹ , Dr Stefan Kassumeh ¹ , Dr Niklas Mohr ¹ , Dr Jascha Wendelstein ¹ , Prof. Dr Siegfried Priglinger ¹ , Dr Lukas Neuhann ¹

¹Department of Ophthalmology ,LMU Munich ,Munich ,Germany

Purpose

To evaluate the effect of topical losartan on corneal scarring independent of etiology, focusing on functional outcomes such as best-corrected visual acuity (BCVA) and contact lens visual acuity, as well as objective parameters including corneal pachymetry, corneal aberrations, keratometric values, corneal density, and corneal tomography measured with MS-39 and Pentacam.

Setting

In this ongoing prospective case study, 24 eyes of 24 patients with corneal scarring were enrolled and treated with topical losartan 0.8 mg/mL four times daily. To date, data from 9 patients are available for analysis. Two patients discontinued treatment due to ocular burning, two experienced recurrence of herpetic keratitis, and two were lost to follow-up. Data from the remaining enrolled patients are not yet available.

Methods

Baseline examinations and follow-up visits at 3, 6, 9, and 12 months included assessment of BCVA, contact lens visual acuity, intraocular pressure (IOP) measured by Goldmann applanation tonometry, and imaging with Pentacam and MS-39. Patients additionally completed a symptom questionnaire at each visit.

Results

Among the analyzed cohort (6 m , 3 f) baseline mean BCVA was 0.53 logMAR (range 0.05–1.0).At the 3-month follow-up, mean BCVA improved to 0.38 logMAR (range 0.05–0.7). Seven of nine eyes showed improvement of one or more lines (p = 0.026), one eye remained unchanged, and one eye lost one line of vision. Preliminary 6-month data were available for five eyes and showed a mean BCVA of 0.33 logMAR (range 0.15–0.7). Four of five eyes gained one or more lines of visual acuity compared with baseline, while one eye remained stable. This improvement did not reach statistical significance (p = 0.065).No significant changes were observed in root mean square higher-order aberrations (RMS-HOA), thinnest corneal thickness (TCT), or intraocular pressure.

Conclusions

Despite the small sample size, a trend toward improved BCVA during treatment with topical losartan was observed. Further follow-up, including 9- and 12-month data and additional MS-39 parameters, will help clarify the potential role of topical losartan in the management of corneal scarring.